Jonathan Chernoff, MD, PhD – Senior Vice President, Chief Scientific Officer
Dr. Chernoff graduated from Yale College in 1978, then entered an MSTP program at the Mt. Sinai School of Medicine, obtaining M.D. and Ph.D. degrees in 1984. He did an Internal Medicine Residency at the University of Pittsburgh, followed by a Medical Oncology Fellowship at Johns Hopkins and at Beth Israel Hospital. Following a postdoctoral fellowship with Ray Erikson at Harvard University, he joined FCCC in 1991 as an Assistant Professor. Dr Chernoff has been leader or co-leader of the Cancer Biology Program and its precursors for over a decade. In September 2008, he became Deputy Scientific Director, and in 2010 was promoted to Chief Scientific Officer.
Dr. Chernoff is an internationally recognized expert in signal transduction, with particular interest in the regulation of cell proliferation and movement by protein kinases and phosphatases. Of note, he identified and characterized the protein kinases Mst1/2 (hippo) and Pak1/2, which represent important human tumor suppressors and oncogenes, respectively. He has been a leader in defining the role of the Pak1 protein in several malignancies, most notably in breast cancer and in Neurofibromatosis I and 2, and, with colleagues at FCCC, has developed the first specific small molecule inhibitors for the Paks. Dr. Chernoff also leads an internationally known program on protein tyrosine phosphatases, with special regard to their role in regulating Neu signaling in breast cancer. He has chaired numerous international meetings on signal transduction and serves as an editor for Molecular Biology of the Cell and Cancer Biology & Therapy, as well as a frequent ad-hoc reviewer for many top-tier science journals.